CTOs on the Move

MAP Pharmaceuticals

www.mappharma.com

 
MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mappharma.com
  • 2400 Bayshore Pkwy Suite 200
    Mountain View, CA USA 94043
  • Phone: 650.386.3100

Executives

Name Title Contact Details

Similar Companies

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.

Clyde Chemists

Clyde Chemists is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GW Pharmaceuticals

GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.

First Boston Pharma

First Boston Pharma, LLC is a Gloucester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cingulate

The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.